Asthma Treatment OTC Switches Would Face Tough Barriers
This article was originally published in The Tan Sheet
Executive Summary
Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.
You may also be interested in...
NDAC Puts Hitch In Oxytrol Switch With Negative Self-Selection Vote
In a 6-5 vote, FDA’s Nonprescription Drugs Advisory Committee said Merck failed to show that consumers can appropriately self-select to use Oxytrol for Women in an OTC setting. The company expects to hear from FDA on its Rx-to-OTC switch application by the end of January.
NDAC Puts Hitch In Oxytrol Switch With Negative Self-Selection Vote
In a 6-5 vote, FDA’s Nonprescription Drugs Advisory Committee said Merck failed to show that consumers can appropriately self-select to use Oxytrol for Women in an OTC setting. The company expects to hear from FDA on its Rx-to-OTC switch application by the end of January.
NDAC Puts Hitch In Oxytrol Switch With Negative Self-Selection Vote
In a 6-5 vote, FDA’s Nonprescription Drugs Advisory Committee said Merck did not show that consumers can appropriately self-select to use Oxytrol for Women in an OTC setting. The company expects to hear from FDA on its Rx-to-OTC switch application by the end of January.